Morgan Stanley analyst Terence Flynn raised the firm’s price target on Eli Lilly to $455 from $440 and keeps an Overweight rating on the shares. While the stock traded down despite a Q4 beat on earnings, the firm attributed that to macro and positioning factors as well as questions on Mounjaro reimbursement dynamics. Though Morgan Stanley admits there is "likely limited upside" to first-half estimates, it continues to see multiple levers to upside in the second half and beyond.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on LLY:
- Eli Lilly’s net price for Mounjaro did not decline in Q4, says Evercore ISI
- Pharma Earnings: Q4 Hits and Misses in a Post-COVID-19 World
- Eli Lilly raises FY23 adjusted EPS view to $8.35-$8.55 from $8.10-$8.30
- Eli Lilly reports Q4 adjusted EPS $2.09, consensus $1.78
- Eli Lilly says FDA approves Jaypirca
